Immunic AG

General information
Immunic AG
Lochhamer Schlag 21
82166 Gräfelfing, Bavaria

Contact person: Jessica Breu, Head of Investor Relations and Communications
Company main phone: +49 (89) 2080 477 00
Year founded:2016
Source of foundation:Subsidiary
Name of foundation source:Immunic, Inc., USA
Corporate description / mission:
Immunic AG is focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The company develops immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and RORγt (IMU-366 program) relevant to diseases such as Ulcerative Colitis, Crohn’s disease and psoriasis.
State of ownership: Subsidiary
Headquarters: No
  • Biotechnology - Therapeutics and Diagnostics
  • Immunotherapy
  • Small molecules
Primary therapeutic areas:
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the nervous system / neurology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • R&D
  • Subsidiary
Customer segments:
  • Hospitals
  • Large biotech & big pharma
Summary Products / Services / Technologies
Description of products:
DHODH (IMU-838 program) and RORγt (IMU-366 program)